Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Grandi, L; Di Giovanni, G; Galati, S; Grandi L. C.; Di Giovanni G.; Galati S.
  • Document Type:
    Electronic Resource
  • Online Access:
    http://hdl.handle.net/10281/284727
    info:eu-repo/semantics/altIdentifier/pmid/30107207
    info:eu-repo/semantics/altIdentifier/wos/WOS:000449447500019
    volume:308
    firstpage:205
    lastpage:218
    numberofpages:14
    journal:JOURNAL OF NEUROSCIENCE METHODS
  • Additional Information
    • Publisher Information:
      Elsevier B.V. 2018
    • Abstract:
      Parkinson's disease is a common neurodegenerative disease characterized by a widely variety of motor and non-motor symptoms. While the motor deficits are only visible following a severe dopamine depletion, neurodegenerative process and some non-motor symptoms are manifested years before the motor deficits. Importantly, chronic degeneration of dopaminergic neurons leads to the development of compensatory mechanisms that play roles in the progression of the disease and the response to anti-parkinsonian therapies. The identification of these mechanisms will be of great importance for improving our understanding of factors with important contributions to the disease course and the underlying adaptive process. To date, most of the data obtained from animal models reflect the late, chronic, dopamine-depleted states, when compensatory mechanisms have already been established. Thus, adequate animal models with which researchers are able to dissect early- and late-phase mechanisms are necessary. Here, we reviewed the literature related to animal models of early-stage PD and pharmacological treatments capable of inducing acute dopamine impairments and/or depletion, such as reserpine, haloperidol and tetrodotoxin. We highlighted the advantages, limitations and the future prospective uses of these models, as well as their applications in the identification of novel agents for treating this neurological disorder.
    • Subject Terms:
    • Availability:
      Open access content. Open access content
    • Note:
      English
    • Other Numbers:
      ITBAO oai:boa.unimib.it:10281/284727
      10.1016/j.jneumeth.2018.08.012
      info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85051408394
      1308935688
    • Contributing Source:
      BICOCCA OPEN ARCH
      From OAIster®, provided by the OCLC Cooperative.
    • Accession Number:
      edsoai.on1308935688
HoldingsOnline